From the Guidelines
Enzar Forte is not the primary treatment for gastric motility issues, and prokinetic agents should be considered instead. Enzar Forte is a medication that contains enzymes, typically pancreatic enzymes like amylase, lipase, and protease, and is primarily used to treat digestive disorders by supplementing digestive enzymes to help break down carbohydrates, fats, and proteins in the digestive tract 1. While it aids in digestion, it does not directly enhance or regulate gastric motility, which is the movement of food through the stomach.
Gastric Motility Treatment
For gastric motility disorders, medications like prokinetics (metoclopramide, domperidone) would be more appropriate as they specifically target and improve the movement of the stomach muscles. According to the study, in patients in whom the predominant symptom is fullness, bloating, or satiety (dysmotility-like dyspepsia), a prokinetic agent is an option 1.
Key Points to Consider
- Enzar Forte may help with digestive symptoms by improving nutrient breakdown, but it won't address the underlying motility dysfunction if that's the primary concern.
- Prokinetic agents are the preferred treatment for gastric motility issues.
- If symptoms persist, a switch of treatment or referral for endoscopy may be necessary, as discussed in the study 1.
Next Steps
If you're experiencing symptoms of delayed gastric emptying or other motility issues, it would be better to consult with a healthcare provider who can recommend appropriate prokinetic agents or other treatments specifically designed to address gastric motility problems.
From the Research
Gastric Motility and Enzar Forte
There is no direct information available on Enzar Forte in the provided studies. However, we can discuss the effects of similar prokinetic agents on gastric motility:
- Itopride, a mixed D2 antagonist and cholinesterase inhibitor, has prokinetic effects on gastric motility 2.
- Itopride significantly improved symptoms in patients with functional dyspepsia in one phase II randomized trial, but the mechanisms by which itopride may improve symptoms are unknown 3.
- In healthy volunteers, itopride reduced total postprandial gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function 3.
Prokinetic Agents and Gastric Motility
Other prokinetic agents, such as metoclopramide and erythromycin, have been studied for their effects on gastric motility:
- Metoclopramide and erythromycin are supported by evidence for their use in promoting gastric emptying 4.
- Dual-drug therapy with erythromycin and metoclopramide reduces the rate of treatment failure 4.
- Ghrelin agonists, highly selective 5-hydroxytryptamine receptor agonists, and opiate antagonists are being studied in clinical trials for their potential effects on gastric motility 4.
Gastric Motility Disorders
Gastric motility disorders, such as gastroparesis, can cause delayed gastric emptying and other symptoms:
- Gastroparesis is characterized by delayed gastric emptying in the absence of mechanical outlet obstruction 5.
- The condition commonly manifests as upper gastrointestinal symptoms, including nausea, vomiting, postprandial fullness, early satiety, abdominal pain, and bloating 5.
- Conventional prokinetic agents, such as metoclopramide and domperidone, form the mainstay of treatment for gastroparesis 5.